Candriam S.C.A. Grows Stock Position in Bicycle Therapeutics plc (NASDAQ:BCYC)

Candriam S.C.A. grew its stake in Bicycle Therapeutics plc (NASDAQ:BCYC - Free Report) by 3.5% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 1,087,876 shares of the company's stock after purchasing an additional 37,278 shares during the period. Candriam S.C.A. owned about 1.58% of Bicycle Therapeutics worth $15,230,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. L & S Advisors Inc boosted its position in Bicycle Therapeutics by 2.4% in the third quarter. L & S Advisors Inc now owns 59,735 shares of the company's stock valued at $1,352,000 after buying an additional 1,400 shares in the last quarter. Assetmark Inc. bought a new position in shares of Bicycle Therapeutics in the 3rd quarter valued at $34,000. JPMorgan Chase & Co. boosted its holdings in shares of Bicycle Therapeutics by 26.8% during the 3rd quarter. JPMorgan Chase & Co. now owns 8,424 shares of the company's stock valued at $191,000 after acquiring an additional 1,782 shares in the last quarter. China Universal Asset Management Co. Ltd. grew its position in Bicycle Therapeutics by 30.7% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 9,329 shares of the company's stock worth $131,000 after acquiring an additional 2,191 shares during the last quarter. Finally, Avior Wealth Management LLC acquired a new position in Bicycle Therapeutics in the 4th quarter worth about $57,000. 86.15% of the stock is owned by institutional investors.

Insider Transactions at Bicycle Therapeutics

In related news, insider Santiago Arroyo sold 4,943 shares of the stock in a transaction dated Thursday, January 2nd. The shares were sold at an average price of $14.09, for a total transaction of $69,646.87. Following the completion of the transaction, the insider now owns 69,057 shares in the company, valued at approximately $973,013.13. This represents a 6.68 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CAO Travis Alvin Thompson sold 2,686 shares of the stock in a transaction on Monday, January 6th. The stock was sold at an average price of $15.00, for a total value of $40,290.00. Following the transaction, the chief accounting officer now owns 32,146 shares of the company's stock, valued at $482,190. The trade was a 7.71 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 27,677 shares of company stock valued at $392,413 in the last 90 days. 8.50% of the stock is currently owned by corporate insiders.

Remove Ads

Wall Street Analyst Weigh In

BCYC has been the topic of several research reports. B. Riley reduced their price target on Bicycle Therapeutics from $28.00 to $17.00 and set a "neutral" rating on the stock in a report on Friday, December 13th. JMP Securities reduced their target price on shares of Bicycle Therapeutics from $32.00 to $26.00 and set a "market outperform" rating on the stock in a report on Wednesday, December 18th. Needham & Company LLC restated a "buy" rating and issued a $30.00 price target on shares of Bicycle Therapeutics in a research report on Wednesday, February 26th. Stephens reiterated an "equal weight" rating and set a $15.00 price target on shares of Bicycle Therapeutics in a report on Wednesday, January 22nd. Finally, HC Wainwright reissued a "buy" rating and issued a $33.00 price objective on shares of Bicycle Therapeutics in a research note on Wednesday, February 26th. Two investment analysts have rated the stock with a hold rating and six have given a buy rating to the company's stock. According to data from MarketBeat, Bicycle Therapeutics has an average rating of "Moderate Buy" and a consensus price target of $29.14.

Bicycle Therapeutics Stock Performance

Shares of NASDAQ:BCYC traded down $0.44 during trading on Monday, reaching $9.79. The stock had a trading volume of 340,149 shares, compared to its average volume of 299,774. Bicycle Therapeutics plc has a 52 week low of $9.58 and a 52 week high of $28.67. The firm's fifty day moving average is $12.77 and its 200 day moving average is $18.84. The stock has a market cap of $675.96 million, a price-to-earnings ratio of -2.98 and a beta of 1.12.

Bicycle Therapeutics (NASDAQ:BCYC - Get Free Report) last issued its quarterly earnings results on Tuesday, February 25th. The company reported ($0.75) EPS for the quarter, beating analysts' consensus estimates of ($0.85) by $0.10. Bicycle Therapeutics had a negative net margin of 450.64% and a negative return on equity of 27.35%. The business had revenue of $3.70 million for the quarter, compared to analysts' expectations of $5.47 million. During the same quarter in the prior year, the firm posted ($1.16) earnings per share. The business's quarterly revenue was down 30.2% compared to the same quarter last year. On average, research analysts forecast that Bicycle Therapeutics plc will post -3.06 earnings per share for the current fiscal year.

Bicycle Therapeutics Profile

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial.